Abcam, ab248219, Anti-FAAH1 antibody [EPR7549] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal FAAH1 antibody. Carrier free. Suitable for IHC-P, WB and reacts with Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR7549,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:IHC-P, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab248219 is the carrier-free version of
ab128917
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Species reactivity
Rat: We have preliminary internal testing data to indicate this antibody may not react with this species.
Please
contact us
for more information.
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Fatty acid amide hydrolase 1 (FAAH1) often referred to simply as FAAH is an enzyme that plays a critical role in the degradation of fatty acid amides such as anandamide in the body. This enzyme weighing approximately 63 kDa is a part of the amidase signature family and is characterized by its amidase hydrolase activity. FAAH1 is predominantly expressed in the nervous system liver and gastrointestinal tract where it hydrolyses amide bonds facilitating the termination of signaling pathways initiated by neurotransmitter-like fatty acid amides.
Biological function summary
FAAH1 is essential for maintaining homeostasis by modulating levels of bioactive lipids. It exerts control over endocannabinoid signaling by breaking down anandamide a lipid derivative functioning as a neurotransmitter. FAAH1 does not act as part of a larger protein complex. Instead it operates alone to regulate the duration and intensity of signaling rather than relying on direct interactions within a complex. The enzyme's function impacts the neurochemical milieu in tissues where it is actively expressed thereby affecting mood pain sensation and more.
Pathways
FAAH1 has a significant role in the endocannabinoid signaling pathway and fatty acid metabolism. Within these pathways it modulates signaling by hydrolysing bioactive amides like anandamide influencing overall lipid signaling. FAAH1 activities intersect with several other proteins such as cannabinoid receptors which bind the substrates that FAAH1 eventually degrades. These interactions are vital in controlling signal transduction processes that regulate physiological responses including stress and analgesia.
FAAH1 has been implicated in conditions like chronic pain and anxiety disorders. Altered FAAH1 function or expression can lead to dysregulation of endocannabinoid signaling contributing to the pathophysiology of these conditions. The enzyme's modulation of anandamide levels connects it to proteins such as CB1 and CB2 cannabinoid receptors which mediate the effects of endocannabinoids in neurological and psychiatric disorders. Research into FAAH1 inhibitors as therapeutic agents highlights its importance in potential treatments for managing pain and anxiety.